Published: 2022-09-30

Multidimensional voice assessment after Lee Silverman Voice Therapy (LSVT®) in Parkinson’s disease

Otorhinolaryngology Head & Neck Surgery Unit, Fondazione Policlinico Universitario “A. Gemelli” - IRCCS - Rome, Italy
Otorhinolaryngology Head & Neck Surgery Unit, Fondazione Policlinico Universitario “A. Gemelli” - IRCCS - Rome, Italy
Otorhinolaryngology Head & Neck Surgery Unit, Fondazione Policlinico Universitario “A. Gemelli” - IRCCS - Rome, Italy
Otorhinolaryngology Head & Neck Surgery Unit, Fondazione Policlinico Universitario “A. Gemelli” - IRCCS - Rome, Italy
Otorhinolaryngology Head & Neck Surgery Unit, Fondazione Policlinico Universitario “A. Gemelli” - IRCCS - Rome, Italy
Head & Neck Department, Università Cattolica del Sacro Cuore, Rome, Italy
Parkinson’s disease Lee Silverman speech treatment acoustic analysis prosody voice dysarthria


Objective. To investigate the effectiveness of Lee Silvermann Voice Treatment (LSVT®) in improving prosody in patients with Parkinson’s disease over medium-term follow-up.
Methods. 15 patients with Parkinson’s disease were assessed before LSVT®, within one week, and 3 and 6 months after treatment. Subjective and objective evaluation included: Voice Handicap Index - 10 (VHI-10), perceptual assessment by GRBAS scale and item 18 of the Unified Parkinson’s Disease Rating Scale III (UPDRS III), maximum phonation time (MPT /s/) and acoustic analysis by means the Voice Range Profile (VRP) and the “Intonation Stimulability Protocol” of the Motor Speech Profile (MSP).
Results. A significant increase of the mean values of Imax and rF0 was observed until 6 months post-therapy (p < 0.001), whereas Running Speech Standard Deviation (rSTD) (p = 0.004), Amplitude Variability (rVAm) (p = 0.02) and Frequency Variability (rvF0) (p = 0-01) improved significantly after 3 months, but returned to pre-therapy levels after 6 months. The score of item 18 of the UPDRS III increased significantly early post-therapy (p = 0.03), but did not maintain the improvement at 3 and 6 months. Median values of Grade (G), Asthenia (A) and mean values VHI-10 score significantly decreased at each post-therapy control (p < 0.05).
Conclusions. In addition to the subjective and perceptual beneficial effect of LSVT®, we found a long-lasting increase of loudness and fundamental frequency. There was also improvement of acoustic parameters related to prosody, although it was temporary.


One of the most common voice symptoms and one of the primary targets of intervention in Parkinson’s disease (PD) is reduced voice intensity. Parkinsonian hypokinetic dysarthria is mainly characterised by breathy and harsh voice, reduced loudness and monotonous speech. Loss in voice production, which occurs along with other speech problems, concerns the majority of patients with PD (90%) 1 and results in a decrease in familiar, social and professional interactions, as well as in isolation and consequent deterioration of quality of life 2. Although the neural mechanisms underlying vocal symptoms are not clear, the combination of bradykinesia/hypokinesia with psychological and sensory components is pointed out as being responsible for voice impairment 3.

As medication and surgical treatments have only modest effects on parkinsonian speech 4-7, behavioural treatments are preferred 8. Intensive voice therapy, specifically Lee Silverman Voice Treatment (LSVT®), has been shown to be highly effective 9. LSVT® trains dysarthric patients with PD to speak louder while self-monitoring the effort required to produce that voice.

This method capitalises on the known effects of increased vocal effort and loudness on the respiratory, phonatory and articulatory subsystems of speech. LSVT® stimulates glottal closure with the aim of increasing vocal intensity and, even if purely focused on voice, of improving articulation by recalibrating the sensorimotor perception of the volume of voice 10. LSVT® increases respiratory drive and improves oral resonance/vocal loudness through increased jaw movements 11. The result is better communication through reduction of vocal symptoms of the disease and adjustment of voice quality to personal and social needs. LSVT® has proven to be effective in Level I Scientific Evidence, and for years has been the treatment of choice for patients with PD as shown by the predominance of studies using it 12. A recent review by Yuan et al. (2020) noted that most trials have considered increased vocal loudness as the main outcome measure of treatment 13, not focusing on prosody as another equally important outcome measure. In fact, it is well known that monotonic speech is one of the most characteristic aspects of parkinsonian dysarthria interfering with the naturalness of speech in these patients.

The aim of our study was to investigate the effectiveness of LSVT® in improving prosody in patients with PD, by using it a specific program for the first time – the “Intonation Stimulability Protocol” – included in the “Motor Speech Profile” (MSP) software (MSP-model 5141, Kay Elemetrics, Lincoln Park, NJ).

Materials and methods

Patients and setting

From April 2019 to November 2019, at the Phoniatric Unit of the Fondazione Policlinico Universitario “A. Gemelli” IRCCS in Rome, we enrolled patients affected by PD. The inclusion criteria were: PD diagnosed by an expert neurologist according to the UK Parkinson’s disease Brain Bank criteria 14; age between 40 and 80 years, H-Y stage no > III, able and willing to provide written informed consent. The exclusion criteria were the following: parkinsonism other than idiopathic PD, previous or current psychiatric problems or cognitive decline, history of voice or laryngeal disease requiring therapy or of pulmonary disease, previous neck surgery, past or present swallowing or voice rehabilitation therapy, bilateral high-frequency stimulation of subthalamic nucleus (STN). The subjects were studied by a team that included a neurologist trained in movement disorders, a speech-language pathologist with over 10 years of experience working with patients affected by PD, two otolaryngologists and two speech-language therapists.


Patients were evaluated before treatment (pre-therapy), within one week after therapy (early post-therapy), and at three and six months after therapy. For each patient the functional assessment was always carried out at the same time of day, one hour after intake of a standardised dosage of levodopa. The author (MRM) involved with data collection was blind to the patients’ status and treatment condition.

Voice therapy

LSVT® was conducted by four of the authors (C.AC, Y.L, G.M., I.P.), certified by LSVT Global Inc., according to its main treatment protocol, published by Ramig et al. 15-17.

The treatment consists of 16 individual therapy sessions (four 1-hour sessions per week for 4 consecutive weeks) and involves multiple repetitions (15 times and more), maximum effort of the individuals, and daily tasks. The complexity of the training increases during the 4 weeks, with greater cognitive/motor load of the exercises, longer duration and higher difficulty of the “speech” tasks assignments. The exercises can be done at home. The treatment program was performed individually in a quiet room. Clinical assignments used in LSVT® were first translated into Italian by a speech and language pathologist who was fluent in both English and Italian.

Objective and subjective assessment

Strobovideolaryngoscopy was performed by an expert, independent and blinded ENT physician (LD), using a flexible laryngoscope (model Xion Gmbh Video-Nasopharyngoscope EV-NE) to exclude morphological abnormalities and motility impairment of the larynx.

Maximum phonation time (MPT /s/). This was obtained by having the patient sustain the vowel /a/ for as long as possible on a single breath. The longest of three attempts was calculated as MPT.

Perceptual voice analysis. Blind perceptual evaluation was performed on recorded voice samples (reading task of 184 words, 362 syllables and 26 sentences) by unfamiliar listeners with expertise in voice disorders. It comprised The Grade – Roughness – Breathiness – Asthenia – Strain (GRBAS) scale18 and item 18 of the Unified Parkinson’s Disease Rating Scale III (UPDRS III), which requires rating speech on a 5-point Likert scale (from 0: Normal - no speech problems - to 4: Severe: most speech is difficult to understand or unintelligible).

Patient self-assessment. Assessment of dysphonia-related quality of life was carried out by using the Italian version of the Voice Handicap Index-10 (VHI-10) 19.

Acoustic voice analysis. For acoustic voice analysis we used the Computerized Speech Lab model 4300B from Kay Elemetrics (Lincoln Park, NJ), recording with a Shure model SM48 microphone (Evanston IL) positioned at a 45° angle and at a distance of 20 cm from patient’s mouth. The microphone saturation input was fixed at 6/9 of Channel 1 and the environmental noise was < 30 dB sound pressure level (SPL). The Voice Range Profile program (VRP-model 4326) was used to analyse speaking voice as described by D’Alatri and Marchese 20. Patients were asked to read twice 20 sentences aloud at their most comfortable pitch and loudness as in daily conversation. Subjects were allowed to practice reading the sentences aloud before actual recording. The sentences were chosen to be characterised by different prosodic features (i.e.: interrogative, affirmative, exclamatory) and to express different feelings (i.e.: happiness, sadness, disbelief, disappointment). After recording, the following parameters were analysed: lowest frequency (Fmin, Hz), he highest frequency (Fmax, Hz), number of semitones (st), minimum intensity (Imin, dB SPL), maximum intensity (Imax, dB SPL) and difference between Imax and Imin (range dB, dB SPL)

Motor Speech Profile (MSP– model 5141) analysis was performed by using the protocol ‘‘Intonation stimulability’’ that assesses the patient’s ability to listen to a target speech token and then verbally match the target intonation pattern. Patients were asked to listen and to repeat the sentence “Esci oggi o domani?” ([‘ɛ∫i ‘ɔʤ:i /↗/ oˬ do’mani /↘/]) in which all the phonemes except one – the fricative palato-alveolar [ʃ]) – are voiced. The sentence was modeled with an upward and downward intonation to evaluate the ability to vary pitch and intensity during speech. In the recording, a sampling rate of 11025 Hz was used. The variables analysed with the “Intonation Stimulability Protocol” were: Running Speech Average Fundamental Frequency (rF0 – Hz), Running Speech Highest Fundamental Frequency (rFhi – Hz), Running Speech Lowest Fundamental Frequency (rFlow – Hz), Running Speech Standard Deviation of F0 (rSTD – Hz), Frequency Variability (rvF0 – %) and Amplitude Variability (rvAm - %). The parameters rSTD and rvF0 track the degree of pitch variations, low values suggesting a monotonic vocalisation. The parameter rvAm tracks the degree of amplitude variability, a mono-level vocalisation corresponding to lower values of rvAm.

Statistical analysis

For statistical analysis we used the MedCalc package (version 12, Marienkerke, Belgium). Kolmogorov–Smirnov test was employed to assess the distribution of the continuous variables examined in the study. Parametric (repeated-measures ANOVA with Bonferroni correction and Student’s t-test for paired data) and non-parametric tests (Wilcoxon) were applied depending on data distribution. The level of significance was set at p < 0.05.


From a series of 23 patients, 8 (34.78%) did not meet inclusion criteria and 15 (65.2%) were thus considered. Of these, 14/15 (93.3%) cases were male and 1/15 (6.6%) was female, with a mean age of 71 ± 7 years (min. 58, max. 78 years). The mean time since diagnosis was 2.6 years (min. 1 and max 5 years).


None of the 15 cases had morphological abnormalities and motility impairment of the larynx.

Maximum phonation time (MPT)

Repeated-measures ANOVA showed no significant difference among the times of observation (p > 0.05). However, Student’s t-test for paired data revealed that MPT significantly improved soon after the end of treatment (mean pre-therapy = 14.81 ± 9.10 s; mean early post-therapy = 17.81 ± 7.83 s, p < 0.02), whereas this MPT increase was no longer significant at 3 months (mean = 16.18 ± 6.82 s, p > 0.05) and 6 months post-therapy (mean = 15.27 ± 5.71 s, p > 0.05).

Acoustic voice analysis

VRP analysis by repeated-measures ANOVA showed a significant increase of Imax (F (3, 34) = 11.03; p < 0.001), and two-by-two comparisons demonstrated that the significant improvement was obtained immediately after treatment and maintained throughout follow-up. Repeated-measures ANOVA did not reveal a significant increase of Fmax over time (p > 0.05). By Student’s t-test for paired data, significant improvement was found between pre-therapy and early post-therapy (p = 0.01), and Fmax tended to decrease at 3 and 6 months post-therapy. At repeated-measures ANOVA, the increase in intensity range (dB) was nearly significant (p = 0.07). As for the above-mentioned variables, Student’s t-test for paired data showed significant improvement between pre-therapy and early post-therapy, after which a decreasing trend was observed. The comparison between pre-therapy, early post-therapy, 3 and 6 months post-therapy did not detect significant differences in the mean number of semitones or mean values of Imin and Fmin (p > 0.05). All data on acoustic voice analysis are detailed in Table I.

At repeated-measures ANOVA, no significant improvement of the rF0 variable was observed over time. Nevertheless, Student’s t-test for paired data showed significant improvement between pre-therapy and early post-therapy (p < 0.001). These results remained stable at 3 and 6 months after therapy. Similarly, the rvF0 and rSTD variables did not increase over time. However, for the rvF0 variable Student’s t-test for paired data showed significant improvement between pre-therapy and 3 months post-therapy (p = 0.01) and for rSTD values Student’s t-test for paired data resulted in a significant increase between pre-therapy and 3 months post-therapy (p = 0.004). With regards to the rvAm variable, repeated-measures ANOVA showed significant improvement over time (F (3, 35) = 39.60; p = 0.02), with significant differences between both pre-therapy and early post-therapy, and between early post-therapy and 3 months post-therapy.

Regarding rFhi and rFlow variables, no significant increase was found over time at repeated-measures ANOVA nor at two-by two comparisons by Student’s t-test. Details concerning the variables rF0, rvF0, rSTD, rvAm, rFHi and rFLo are reported in Table II.

Perceptual voice analysis

A Wilcoxon Test was applied in order to analyse GRBAS and item 18 of UPDRS III scores. The Grade (G) variable decreased significantly between pre-therapy and early post-therapy (p = 0.003) and between pre-therapy and the two follow-up assessments after 3 (p = 0.007) and 6 months (p = 0.03). At the early and 3 months post-therapy time points, median values for Asthenia (A) were significantly decreased compared with pre-therapy ones (p = 0.03; p = 0.01 respectively) (Fig. 1).

With regards to the UPDRS III results, the score of item 18 significantly improved at the early post-therapy control (median pre-therapy = 1, median early post-therapy = 0, p = 0.03), but it did not at the 3 and 6 months post-therapy follow-up (p > 0.05).

Patient self-assessment

The VHI-10 mean scores before and after voice therapy are shown in Figure 2. The mean values analysed by repeated-measures ANOVA did not detect any significant decrement over time. Nevertheless, Student’s t-test for paired data revealed a significant improvement (p = 0.04) between pre-therapy (mean = 1 6.67 ± 8.63) and early post-therapy (mean = 11.23 ± 5.80), and between pre-therapy and the two follow-up assessments at 3 (mean 10.57 ± 10.70) (p = 0.01) and 6 months (mean = 10.14 ± 6.64) (p = 0.01), as shown in Figure 2.

Discussion and conclusions

The aim of this study was to investigate the effectiveness of LSVT® in improving prosody in patients with PD. For this purpose, we analysed the acoustic parameters related to prosody using software specifically designed for motor speech disorders.

Clinical research 21-23 on PD has demonstrated that, even if dysarthria may impact all speech subsystems, vocal loudness and prosody are the most affected, impairing naturalness and speech intelligibility.

Ramig et al. 15,16 demonstrated that LSVT® improves both parameters related to vocal loudness (e.g. SPL during vowels and reading) and those related to prosody (e.g. fundamental frequency variability in monologue, inflection in voice fundamental frequency), even in the long term.

In our group of patients, the mean values of Imax as well as those of rF0 increased significantly immediately after LSVT® and did not change until the last follow-up. The simultaneous increase in intensity and frequency was predictable, since, as is known, the fundamental frequency increases with intensity 21.

In contrast with Ramig et al. 15,16, the increase in the average fundamental frequency of running speech we observed in our patients after therapy did not relate to improvement in prosody. Indeed, in our study the prosody-related acoustic parameters - rSTD, rvF0 and rvAm - showed a significant increase in the medium term, but did not preserve the effect at the last control.

Subjectively, patients showed a significant decrease in voice-related quality of life immediately after therapy and at each time of follow-up. The overall perception of the severity of dysphonia improved until the 6-month control, in particular due to the decrease in Grade and Asthenia, as also confirmed by the results of VHI-10.

Works assessing vocal function after LSVT® described long-term improvement (up to 2 years) basing both on acoustic (SPL and semitone standard deviation) 15 and perceptual data 15-17. Our results show that, thanks to the increase in vocal fold tension and subglottal pressure associated with the increase in volume, LSVT® allows patients to improve vocal fold adduction and the activation and synergy of the laryngeal muscle, thus making the phonatory system more efficient over time.

On the contrary, the recovery of prosody proved to be slower and temporary. It cannot be excluded that rehabilitation of muscle activity aimed at intonation is more difficult and may require repeated therapy cycles to obtain more stable acoustic results. In this regard, the central sensory processing and cueing deficits found in subjects with PD may also play a role. In particular, in patients with PD a selective difficulty in recognising emotions from prosody and a general defect in prosody processing has been demonstrated 23.

One further element that is worth discussing is the fact that several variables considered in our study (MPT, Fmax, range dB, rFlow, rSTD, rvF0, rvAm) improved significantly immediately after therapy or in the medium-term follow-up, but tended to decrease during long-term follow-up, and in some cases even regressing to pre-therapy levels. This finding has never been reported in the literature and may be explained by considering that LSVT® must necessarily be continued by patients themselves once treatment in presence is concluded. This could result difficult to obtain in patients that are seldom monitored in their self-training and need continuous family involvement. Finally, long-term improvements can be compromised by a worsening of general clinical conditions, as is often the case with PD.

Further studies are needed to confirm these results by analysing speech outcomes using tools more specific for PD patients as the Italian protocol for dysarthria (QoL-Dys) 24 and the Italian version of the Frenchay dysarthria Assessment (FDA) 25.

Conflict of interest statement

The authors declare no conflict of interest.


This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author contributions

MRM: design of the study, interpretation of the data and manuscript writing, revision and final approval. IP: acquisition, analysis and interpretation of data, revision and final approval of manuscript. YL: acquisition, analysis and interpretation of the data and manuscript revision. GM: statistical analysis and interpretation of the data, manuscript writing, revision and final approval. CAC: acquisition, analysis and interpretation of data, revision and final approval of manuscript. LD’A: design of the study, interpretation of data, revision and final approval of the manuscript.

Ethical consideration

This research work was conducted in accordance with the principles contained in the Helsinki declaration and was approved by the institutional review board (Fondazione Policlinico Gemelli, Protocol number: 0038806/21). A written consent was obtained from all the patients included in the study after being informed verbally about the aim of the study.

Figures and tables

Figure 1.Results of perceptive assessment basing on the GIRBAS scale.

Figure 2.Self-assessment results (VHI-10) before and after therapy.

Pre LSVT® Early Post-LSVT® 3 months post-LSVT® 6 months post-LSVT®
Imin (dB SPL) 70.91 ± 2.70 72.09 ± 3.08 71.83 ± 2.71 72.13 ± 3.68
Imax (dB SPL) 89.82 ± 4.07 97.45 ± 2.66 * 96 ± 3.85 * 95.13 ± 3 *
Fmin (/Hz/) 122.24 ± 27.29 125.63 ± 30.82 125.40 ± 24.23 130.45 ± 27.32
Fmax (/Hz/) 224 ± 39 268 ± 70 * 253 ± 61.39 246.31 ± 37.27
N. of semitones 10.73 ± 2.24 12 ± 4.98 12.50 ± 3.67 11.88 ± 1.81
range dB 18.90 ± 2.91 25.36 ± 2.54* 17.63 ± 11.70 16.72 ± 10.90
Table I.The results of speech range profile before and after LSVT®.
Pre LSVT® Early Post-LSVT® 3 months post-LSVT® 6 months post-LSVT®
rF0 (/Hz/) 173.18 ± 27.64 199.63 ± 39.59* 201.36 ± 34.57 * 200.63 ± 34.14 *
rFhi (/Hz/) 265 ± 52.54 282.73 ± 58.25 283.72 ± 59.38 279.18 ± 55.80
rFlow (/Hz/) 112.29 ± 19.65 122.98 ± 44.72 133.22 ± 45 * 124.21 ± 34.23
rSTD (/Hz/) 23.77 ± 8.81 30.38 ± 14.63 36.24 ± 17.31 * 24.07 ± 16.79
rvF0 (/%/) 13.11 ± 4.08 15.35 ± 5.84 18.54 ± 8.46* 14.46 ± 5.07
rvAm (/%/) 36.34 ± 4.14 43.20 ± 7.35* 44.69 ± 8.15 * 40.21 ± 3.57
Table II.Values obtained before and after therapy by the Intonation Stimulability Protocol.


  1. Halpern AE, Ramig LO, Matos CE. Innovative technology for the assisted delivery of intensive voice treatment (LSVT LOUD) for Parkinson disease. Am J Speech Lang Pathol. 2012; 21:354-367. DOI
  2. Reynolds AL, Vick JL, Haak NJ. Telehealth applications in speech-language pathology: a modified narrative review. J Telemed Telecare. 2009; 15:310-316. DOI
  3. Ramig LO, Fox C, Sapir S. Speech treatment for Parkinson’s disease. Expert Rev Neurother. 2008; 8:297-309. DOI
  4. Plowman-Prine EK, Okun MS, Sapienz CM. Perceptual characteristics of Parkinsonian speech: a comparison of the pharmacological effects of levodopa across speech and non- speech motor systems. Neuro Rehabilitation. 2009; 24:131-144. DOI
  5. Schulz GM, Hosey LA, Bradberry TJ. Selective left, right and bilateral stimulation of subthalamic nuclei in Parkinson’s disease: differential effects on motor, speech and language function. J Parkinsons Dis. 2012; 2:29-40. DOI
  6. Karlsson F, Olofsson K, Blomstedt P. Articulatory closure proficiency in patients with Parkinson’s disease following deep brain stimulation of the subthalamic nucleus and caudal zona incerta. J Speech Lang Hear Res. 2014; 57:1178-1190. DOI
  7. Atkinson-Clement C, Sadat J, Pinto S. Behavioral treatments for speech in Parkinson’s disease: meta-analyses and review of the literature. Neurodegener Dis Manag. 2015; 5:233-248. DOI
  8. Ho AK, Bradshaw JL, Iansek R. Speech volume regulation in Parkinson’s disease: effects of implicit cues and explicit instructions. Neuropsychologia. 1999; 37:1453-1460. DOI
  9. Tingting P, Min H, Xiangyu K. Lee Silverman voice treatment to improve speech in Parkinson’s disease: a systemic review and meta-analysis. Parkinsons Dis. 2021; 27(2021):3366870. DOI
  10. Wight S, Miller N. Lee Silverman voice treatment for people with Parkinson’s: audit of outcomes in a routine clinic. Int J Lang Commun Disord. 2015; 50:215-225. DOI
  11. Sapir S, Spielman JL, Ramig LO. Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on vowel articulation in dysarthric individuals with idiopathic Parkinson disease: acoustic and perceptual findings. J Speech Lang Hear Res. 2007; 50:899-912. DOI
  12. Coutinho SB, Diaféria G, Oliveira G. Voice and speech of individuals with Parkinson’s Disease during amplification, delay and masking situations. Pró-Fono R Atual Cient. 2009; 21:219-224. DOI
  13. Yuan F, Guo X, Wei X. Lee Silverman Voice Treatment for dysarthria in patients with Parkinson’s disease: a systematic review and meta-analysis. Eur J Neurol. 2020; 27:1957-1970. DOI
  14. National Institute for Health and Care Excellence. Parkinson’s disease in adults: diagnosis and management. 2017. Publisher Full Text
  15. Ramig LO, Sapir S, Countryman S. Intensive voice treatment (LSVT) for patients with Pakinson’s disease: a 2 year follow-up. J Neurol Neurosurg Psychiatry. 2001; 71:493-498. DOI
  16. Ramig LO, Countryman S, Thompson LL. Comparison of two forms of intensive speech treatment for Parkinson’s disease. J Speech Lang Hear Res. 1995; 38:1232-1251. DOI
  17. Sapir S, Ramig LO, Fox CM. Intensive voice treatment in Parkinson’s disease: Lee Silverman voice treatment. Expert Rev Neurother. 2011; 11:815-830. DOI
  18. Hirano M. Clinical examination of voice. Springer-Verlag: New York, NY; 1981.
  19. Forti S, Amico M, Zambarbieri A. Validation of the Italian Voice Handicap Index-10. J Voice. 2014; 28:263. DOI
  20. D’Alatri L, Marchese MR. The speech range profile (SRP): an easy and useful tool to assess vocal limits. Acta Otorhinolaryngol Ital. 2014; 34:253-258.
  21. Alharbi GG, Cannito MP, Buder EH. Spectral/cepstral analyses of phonation in Parkinson’s disease before and after voice treatment: a preliminary study. Folia Phoniatr Logop. 2019; 71:275-285. DOI
  22. Dromey C, Ramig LO. Intentional changes in sound pressure level and rate: their impact on measures of respiration, phonation, and articulation. J Speech Hear Res. 1998; 41:1003-1118. DOI
  23. Albuquerque L, Martins M, Coelho M. Advanced Parkinson disease patients have impairment in prosody processing. J Clin Exp Neuropsychol. 2016; 38:208-216. DOI
  24. Piacentini V, Zuin A, Cattaneo D. Reliability and validity of an instrument to measure quality of life in the dysarthric speaker. Folia Phoniatr Logop. 2011; 63:289-289.
  25. Riolo V, Pizzorni N, Guanziroli E. Cross-cultural adaptation into Italian and validation of the Frenchay Dysarthria. Eur J Phys Rehabil Med. 2022; 58:342-351. DOI


Maria Raffaella Marchese

Otorhinolaryngology Head & Neck Surgery Unit, Fondazione Policlinico Universitario “A. Gemelli” - IRCCS - Rome, Italy

Ilaria Proietti

Otorhinolaryngology Head & Neck Surgery Unit, Fondazione Policlinico Universitario “A. Gemelli” - IRCCS - Rome, Italy

Ylenia Longobardi

Otorhinolaryngology Head & Neck Surgery Unit, Fondazione Policlinico Universitario “A. Gemelli” - IRCCS - Rome, Italy

Giorgia Mari

Otorhinolaryngology Head & Neck Surgery Unit, Fondazione Policlinico Universitario “A. Gemelli” - IRCCS - Rome, Italy

Carolina Ausili Cefaro

Otorhinolaryngology Head & Neck Surgery Unit, Fondazione Policlinico Universitario “A. Gemelli” - IRCCS - Rome, Italy

Lucia D'Alatri

Head & Neck Department, Università Cattolica del Sacro Cuore, Rome, Italy


© Società Italiana di Otorinolaringoiatria e chirurgia cervico facciale , 2022

  • Abstract viewed - 1284 times
  • PDF downloaded - 526 times